Open Access Articles- Top Results for PL-6983


Clinical data
Chemical data

PL-6983 is a selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction.[1][2][3] It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of a side effect of increased blood pressure seen with the latter in clinical trials.[3][1] Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.[3][1]

See also


  1. 1.0 1.1 1.2 Natasha Mitchner (2009). Hypoactive Sexual Desire Disorder in Women: Implications for Family Practice (PDF). Dowden Health Media. 
  2. Simon JA (2009). "Opportunities for intervention in HSDD" (PDF). J Fam Pract 58 (7 Suppl Hypoactive): S26–30. PMID 19825316. 
  3. 3.0 3.1 3.2 Michael L. Krychman; Sandra Finestone (25 October 2010). 100 Questions & Answers About Breast Cancer Sensuality, Sexuality and Intimacy. Jones & Bartlett Publishers. pp. 120–. ISBN 978-1-4496-1936-7. 

External links